{"id":50821,"date":"2025-12-15T20:33:46","date_gmt":"2025-12-15T12:33:46","guid":{"rendered":"https:\/\/flcube.com\/?p=50821"},"modified":"2025-12-15T20:34:55","modified_gmt":"2025-12-15T12:34:55","slug":"amgens-uplizna-scores-third-fda-indication-in-myasthenia-gravis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50821","title":{"rendered":"Amgen\u2019s Uplizna Scores Third FDA Indication in Myasthenia Gravis"},"content":{"rendered":"\n

Amgen Inc.<\/strong> (NASDAQ: AMGN<\/a>) announced that the U.S. FDA approved Uplizna (inebilizumab-cdon)<\/strong> for adult patients with anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravis (gMG)<\/strong>, marking the drug\u2019s third approved indication<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Details<\/th><\/tr><\/thead>
Approval Date<\/strong><\/td>11\u202fDec\u202f2025<\/td><\/tr>
Agency<\/strong><\/td>U.S. FDA<\/td><\/tr>
Product<\/strong><\/td>Uplizna (inebilizumab-cdon)<\/td><\/tr>
New Indication<\/strong><\/td>gMG patients with anti-AChR or anti-MuSK antibodies<\/td><\/tr>
Mechanism<\/strong><\/td>CD19 B cell depleting antibody<\/td><\/tr>
Dosing<\/strong><\/td>300\u202fmg IV infusion every 6 months<\/td><\/tr>
Innovation<\/strong><\/td>Third indication for Uplizna; first CD19-directed therapy for MuSK-positive gMG<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Evidence & Safety Profile<\/h2>\n\n\n\n
Prior Indications<\/th>Approval Date<\/th>Population<\/th><\/tr><\/thead>
NMOSD (AQP4\u2011positive)<\/strong><\/td>June\u202f2020<\/td>Neuromyelitis optica spectrum disorder<\/td><\/tr>
IgG4\u2011RD<\/strong><\/td>April\u202f2025<\/td>Immunoglobulin G4\u2011related disease<\/td><\/tr>
gMG (AChR\/MuSK\u2011positive)<\/strong><\/td>Dec\u202f2025<\/td>~85% of generalized myasthenia gravis patients<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Safety:<\/strong> Consistent with established profile; infusion reactions managed with premedication.<\/p>\n\n\n\n

Market Opportunity & Competitive Landscape<\/h2>\n\n\n\n
Metric<\/th>Value<\/th>Context<\/th><\/tr><\/thead>
US gMG Prevalence<\/strong><\/td>20,000\u201140,000 patients<\/td>~85% are AChR\/MuSK\u2011positive<\/td><\/tr>
US gMG Market Size<\/strong><\/td>$1.2\u202fbillion (2025)<\/td>Dominated by Soliris, Vyvgart, and Ultomiris<\/td><\/tr>
Uplizna Peak US Sales (gMG)<\/strong><\/td>$300\u2011500\u202fmillion<\/strong> by 2029<\/td>15\u201120% market share in gMG segment<\/td><\/tr>
Competitive Advantage<\/strong><\/td>CD19 depletion<\/strong> offers broad B\u2011cell knockdown<\/td>Differentiated vs. FcRn blockers<\/td><\/tr>
Global Expansion<\/strong><\/td>Potential EU\/Japan filings for gMG in 2026\u20112027<\/td>Expands beyond US market<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Licensing History & China Rights<\/h2>\n\n\n\n
Timeline<\/th>Event<\/th><\/tr><\/thead>
May\u202f2019<\/strong><\/td>Hansoh Pharma (HKG: 3692<\/a>) licenses inebilizumab from Viela Bio for mainland China, Hong Kong, Macau<\/td><\/tr>
2021<\/strong><\/td>Viela Bio acquired by Horizon Therapeutics<\/td><\/tr>
2023<\/strong><\/td>Horizon acquired by Amgen; rights transfer complete<\/td><\/tr>
Expected Filing<\/strong><\/td>Hansoh to submit gMG NDA in China by 2026<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding Uplizna\u2019s market penetration, competitive positioning, and global expansion. Actual results may differ due to pricing negotiations, payer coverage decisions, and competitive responses from FcRn and complement inhibitors.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Amgen Inc. (NASDAQ: AMGN) announced that the U.S. FDA approved Uplizna (inebilizumab-cdon) for adult patients…<\/p>\n","protected":false},"author":1,"featured_media":50822,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[330,363,1182,912,15,24,3594],"class_list":["post-50821","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-amgen","tag-hansoh-pharmaceutical","tag-hkg-3692","tag-nasdaq-amgn","tag-product-approvals","tag-rare-orphan-disease-drugs","tag-viela-bio"],"yoast_head":"\nAmgen\u2019s Uplizna Scores Third FDA Indication in Myasthenia Gravis - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Amgen Inc. (NASDAQ: AMGN) announced that the U.S. FDA approved Uplizna (inebilizumab-cdon) for adult patients with anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravis (gMG), marking the drug\u2019s third approved indication.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=50821\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amgen\u2019s Uplizna Scores Third FDA Indication in Myasthenia Gravis\" \/>\n<meta property=\"og:description\" content=\"Amgen Inc. (NASDAQ: AMGN) announced that the U.S. FDA approved Uplizna (inebilizumab-cdon) for adult patients with anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravis (gMG), marking the drug\u2019s third approved indication.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=50821\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-15T12:33:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-15T12:34:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1502.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50821#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50821\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Amgen\u2019s Uplizna Scores Third FDA Indication in Myasthenia Gravis\",\"datePublished\":\"2025-12-15T12:33:46+00:00\",\"dateModified\":\"2025-12-15T12:34:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50821\"},\"wordCount\":286,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50821#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1502.webp\",\"keywords\":[\"Amgen\",\"Hansoh Pharmaceutical\",\"HKG: 3692\",\"NASDAQ: AMGN\",\"Product approvals\",\"Rare \\\/ orphan disease drugs\",\"Viela Bio\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50821#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50821\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=50821\",\"name\":\"Amgen\u2019s Uplizna Scores Third FDA Indication in Myasthenia Gravis - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50821#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50821#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1502.webp\",\"datePublished\":\"2025-12-15T12:33:46+00:00\",\"dateModified\":\"2025-12-15T12:34:55+00:00\",\"description\":\"Amgen Inc. (NASDAQ: AMGN) announced that the U.S. FDA approved Uplizna (inebilizumab-cdon) for adult patients with anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravis (gMG), marking the drug\u2019s third approved indication.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50821#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50821\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50821#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1502.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1502.webp\",\"width\":1080,\"height\":608,\"caption\":\"Amgen\u2019s Uplizna Scores Third FDA Indication in Myasthenia Gravis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50821#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amgen\u2019s Uplizna Scores Third FDA Indication in Myasthenia Gravis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Amgen\u2019s Uplizna Scores Third FDA Indication in Myasthenia Gravis - Insight, China's Pharmaceutical Industry","description":"Amgen Inc. (NASDAQ: AMGN) announced that the U.S. FDA approved Uplizna (inebilizumab-cdon) for adult patients with anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravis (gMG), marking the drug\u2019s third approved indication.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=50821","og_locale":"en_US","og_type":"article","og_title":"Amgen\u2019s Uplizna Scores Third FDA Indication in Myasthenia Gravis","og_description":"Amgen Inc. (NASDAQ: AMGN) announced that the U.S. FDA approved Uplizna (inebilizumab-cdon) for adult patients with anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravis (gMG), marking the drug\u2019s third approved indication.","og_url":"https:\/\/flcube.com\/?p=50821","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-15T12:33:46+00:00","article_modified_time":"2025-12-15T12:34:55+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1502.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=50821#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=50821"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Amgen\u2019s Uplizna Scores Third FDA Indication in Myasthenia Gravis","datePublished":"2025-12-15T12:33:46+00:00","dateModified":"2025-12-15T12:34:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=50821"},"wordCount":286,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=50821#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1502.webp","keywords":["Amgen","Hansoh Pharmaceutical","HKG: 3692","NASDAQ: AMGN","Product approvals","Rare \/ orphan disease drugs","Viela Bio"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=50821#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=50821","url":"https:\/\/flcube.com\/?p=50821","name":"Amgen\u2019s Uplizna Scores Third FDA Indication in Myasthenia Gravis - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=50821#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=50821#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1502.webp","datePublished":"2025-12-15T12:33:46+00:00","dateModified":"2025-12-15T12:34:55+00:00","description":"Amgen Inc. (NASDAQ: AMGN) announced that the U.S. FDA approved Uplizna (inebilizumab-cdon) for adult patients with anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravis (gMG), marking the drug\u2019s third approved indication.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=50821#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=50821"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=50821#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1502.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1502.webp","width":1080,"height":608,"caption":"Amgen\u2019s Uplizna Scores Third FDA Indication in Myasthenia Gravis"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=50821#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Amgen\u2019s Uplizna Scores Third FDA Indication in Myasthenia Gravis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1502.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50821","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50821"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50821\/revisions"}],"predecessor-version":[{"id":50824,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50821\/revisions\/50824"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/50822"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50821"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50821"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50821"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}